BioAge Labs, Inc. (NASDAQ:BIOA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $43.50.

Several research analysts have weighed in on the stock. BTIG Research initiated coverage on shares of BioAge Labs in a research report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Friday, April 24th. Roth Mkm started coverage on BioAge Labs in a report on Wednesday. They issued a “buy” rating and a $36.00 target price on the stock. Oppenheimer started coverage on BioAge Labs in a research report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 target price on the stock. Finally, Citigroup boosted their price target on BioAge Labs from $15.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, March 10th.

BioAge Labs Stock Up 0.6%

BioAge Labs stock opened at $17.05 on Friday. The business has a 50-day simple moving average of $17.45 and a two-hundred day simple moving average of $16.44. The company has a market cap of $757.87 million, a P/E ratio of -7.10 and a beta of 0.99. BioAge Labs has a 52-week low of $3.88 and a 52-week high of $24.00.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.19. The firm had revenue of $2.77 million for the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. Research analysts anticipate that BioAge Labs will post -2.59 EPS for the current fiscal year.

Institutional Investors Weigh In On BioAge Labs

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC lifted its stake in shares of BioAge Labs by 39.9% during the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after buying an additional 1,053 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in BioAge Labs by 24.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,808 shares of the company’s stock valued at $196,000 after buying an additional 2,917 shares in the last quarter. Barclays PLC increased its position in BioAge Labs by 9.3% in the fourth quarter. Barclays PLC now owns 37,780 shares of the company’s stock worth $500,000 after purchasing an additional 3,222 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after buying an additional 3,517 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in BioAge Labs during the third quarter valued at approximately $27,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.